Get the Stockscreener App
9.79
0.93%
0.09
Corbus Pharmaceuticals Holdings Inc stock is traded at $9.79, with a volume of 157.94K.
It is up +0.93% in the last 24 hours and up +12.53% over the past month.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
See More
Previous Close:
$9.70
Open:
$9.78
24h Volume:
157.94K
Relative Volume:
1.08
Market Cap:
$119.98M
Revenue:
$1.54M
Net Income/Loss:
$-38.70M
P/E Ratio:
-2.0964
EPS:
-4.67
Net Cash Flow:
$-36.86M
1W Performance:
+5.84%
1M Performance:
+12.53%
6M Performance:
+19.68%
1Y Performance:
-83.55%
1-Day Range:
$9.5048
$10.18
1-Week Range:
$8.88
$10.18
52-Week Range:
$4.64
$61.72
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Name
Corbus Pharmaceuticals Holdings Inc
Sector
Industry
Phone
617-963-0103
Address
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
9.79 | 113.36M | 1.54M | -38.70M | -36.86M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Initiated | Wedbush | Outperform |
| Jul-22-24 | Resumed | H.C. Wainwright | Buy |
| Jun-26-24 | Initiated | B. Riley Securities | Buy |
| Jun-03-24 | Reiterated | Oppenheimer | Outperform |
| May-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-06-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-08-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-08-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-08-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-08-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-07-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Mar-26-20 | Initiated | Nomura | Buy |
| Apr-05-19 | Initiated | Jefferies | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jan-11-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-26-18 | Initiated | H.C. Wainwright | Buy |
| Dec-07-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-18 | Initiated | B. Riley FBR | Buy |
| Jan-19-18 | Initiated | Raymond James | Outperform |
| Dec-14-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-08-17 | Reiterated | Noble Financial | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Mar-30-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-11-16 | Reiterated | Noble Financial | Buy |
View All
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Latest News
Volume Surge May Signal Institutional Interest in Corbus Pharmaceuticals Holdings Inc.July 2025 Setups & Community Driven Trade Alerts - beatles.ru
Published on: 2025-08-17 09:14:34 - metal.it
Published on: 2025-08-16 20:39:17 - metal.it
Published on: 2025-08-16 18:59:42 - metal.it
Can Corbus Pharmaceuticals Holdings Inc. keep up with sector leadersJuly 2025 Macro Moves & Smart Swing Trading Alerts - thegnnews.com
Fibonacci Support Holding Strong in Corbus Pharmaceuticals Holdings Inc.Trade Volume Report & AI Driven Price Predictions - kangso.co.kr
What is the next catalyst for Corbus Pharmaceuticals Holdings Inc.Free Trading Indicator Pack - thegnnews.com
Can Cannabis Stocks Reverse Their Prolonged Downtrend? - The Globe and Mail
Oppenheimer Lowers Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target to $53.00 - Defense World
Corbus Pharmaceuticals Reports Q2 2025 Financials and Updates - TipRanks
William Blair Issues Negative Outlook for CRBP Earnings - Defense World
Using flow based indicators on Corbus Pharmaceuticals Holdings Inc.Free Real Time Stock Movement Analysis - Newser
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛
How moving averages guide Corbus Pharmaceuticals Holdings Inc. tradingSwing Candidate List with Trade Cues - Newser
Oppenheimer Maintains Outperform Rating for CRBP with Lowered Price Target of $53.00 - AInvest
Oppenheimer Maintains Outperform Rating for CRBP, Lowers Price T - GuruFocus
Corbus Pharmaceuticals: Q2 Earnings Snapshot - New Haven Register
Corbus (CRBP) Q2 Loss Beats Estimates - AOL.com
Key metrics from Corbus Pharmaceuticals Holdings Inc.’s quarterly dataSummary of Long-Term Buy Zone Stocks - Newser
Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewswire
Corbus Pharmaceuticals Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Corbus Pharmaceuticals Receives FDA Fast Track Designation - TipRanks
Corbus Pharmaceuticals Q2 basic eps usd -1.44 - MarketScreener
Corbus Pharmaceuticals (CRBP) Gears Up for Pivotal Data Presentations in Late 2025 - GuruFocus
Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update | CRBP Stock News - GuruFocus
Corbus Advances 3 Clinical Programs: Obesity Drug Trial Expands, Cancer Data Coming to ESMO - Stock Titan
Is Corbus Pharmaceuticals Holdings Inc. stock overvalued or undervaluedBuild wealth steadily with smart trading - Jammu Links News
Is Corbus Pharmaceuticals Holdings Inc. a growth stock or a value stockSkyrocketing investment returns - Jammu Links News
Is Corbus Pharmaceuticals Holdings Inc. a good long term investmentFree Stock Market Return Analysis - Jammu Links News
What is the risk reward ratio of investing in Corbus Pharmaceuticals Holdings Inc. stockGet timely alerts on market opportunities - Jammu Links News
Is it the right time to buy Corbus Pharmaceuticals Holdings Inc. stockExplosive portfolio gains - Jammu Links News
What are the latest earnings results for Corbus Pharmaceuticals Holdings Inc.Superior profit margins - Jammu Links News
When is Corbus Pharmaceuticals Holdings Inc. stock expected to show significant growthDiscover breakthrough stocks before the crowd - Jammu Links News
What analysts say about Corbus Pharmaceuticals Holdings Inc. stockInvest smarter with data-backed trading alerts - Jammu Links News
What are Corbus Pharmaceuticals Holdings Inc. company’s key revenue driversFree Stock Review Backed By Experts - Jammu Links News
What is B. Riley’s Forecast for CRBP Q2 Earnings? - Defense World
What is the dividend policy of Corbus Pharmaceuticals Holdings Inc. stockFinancial News Target Finder For Smart Trading - Jammu Links News
Why is Corbus Pharmaceuticals Holdings Inc. stock attracting strong analyst attentionReal Time Tracker For Fast Growth - Jammu Links News
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Recommendation of “Buy” by Brokerages - Defense World
Corbus Pharmaceuticals stock rises after ESMO abstract acceptance By Investing.com - Investing.com Australia
Dermatomyositis Treatment Market 2034: EMA, PDMA, FDA - openPR.com
Corbus Pharmaceuticals Announces Upcoming Presentation of - GlobeNewswire
Corbus to present updated CRB-701 cancer drug data at ESMO 2025 By Investing.com - Investing.com South Africa
Corbus to present updated CRB-701 cancer drug data at ESMO 2025 - Investing.com Nigeria
Corbus Pharmaceuticals stock rises after ESMO abstract acceptance - Investing.com
CRBP: B. Riley Maintains Buy Rating with Promising Drug Potential - GuruFocus
Corbus Pharmaceuticals (CRBP) to Present Phase 1/2 Study Data at ESMO 2025 - GuruFocus
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Altmeyer Anne | Director |
May 30 '25 |
Sale |
7.25 |
1,392 |
10,096 |
1,391 |
| Smethurst Dominic | Chief Medical Officer |
Mar 06 '25 |
Sale |
6.78 |
6,393 |
43,330 |
70,807 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):